Drug Trial Radar · NCT01035229
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Last checked: Nov 20, 2026Latest source record: Sep 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
546
Actual
Start
Apr 2010
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib.
Conditions
- Carcinoma
Interventions
EverolimusDrug
Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
Everolimus PlaceboDrug
Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
Best Supportive Care (BSC)Other
BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: When 454 OS events were observed
Locations
131 sites in 18 countries. Site status is shown where the registry gives one.
Highlands Oncology Group Dept of Highlands Oncology Grp
Fayetteville, Arkansas
Compassionate Cancer Care Medical Group CCCMG
Fountain Valley, California
University of California San Diego - Moores Cancer Center SC - 3
La Jolla, California
California Pacific Medical Center California Pacific Med
San Francisco, California
Rocky Mountain Cancer Centers RMCC - Denver-Midtown (4)
Greenwood Village, Colorado
Queen's Medical Center Queens Cancer Center
Honolulu, Hawaii
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU
Baltimore, Maryland
Massachusetts General Hospital Dept. of Mass General Hospital
Boston, Massachusetts
Midwest Cancer Care Physicians Research Medical Center
Kansas City, Missouri
VA Sierra Nevada Health Care System Dept. of VA Sierra Nevada HCS
Reno, Nevada
University of Rochester Medical Center Rochester
Rochester, New York
Northwest Cancer Specialists Rose Quarter Cancer Center
Portland, Oregon
St. Luke's Hospital and Health Network St. Luke's Cancer Network (2)
Bethlehem, Pennsylvania
Texas Cancer Center - Abilene
Abilene, Texas
Methodist Charlton Cancer Center Methodist
Dallas, Texas
University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3)
Dallas, Texas
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio
San Antonio, Texas
Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care
Roanoke, Virginia
University of Washington Cancer Care SC
Seattle, Washington
Novartis Investigative Site
Camperdown, New South Wales, Australia
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Heidelberg, Victoria, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Innsbruck, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Edegem, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Xi’an, Shanxi, China
Novartis Investigative Site
Chengdu, Sichuan, China
Showing 40 of 131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.